Nephris
Nephris is a pre-clinical biotech company developing first-in-class therapies for chronic kidney diseases. Based in Milan, Italy, the company was founded by Paolo Fiorina, full professor of Endocrinology at the University of Milan and world-renowned authority in the domain, and Dr. Francesca D’Addio. The company was established through a €3 million seed financing from Sofinnova Telethon Fund.
Sector
Biopharmaceuticals
Strategies
Telethon
Status
Active
Website
www.nephris.com
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.